Early instillation of bladder cancer is usually useful. Immediate bladder perfusion chemotherapy after transurethral bladder tumor electrodessication for bladder cancer can significantly reduce the recurrence rate of non-muscle invasive bladder cancer. The principle is that immediate postoperative perfusion chemotherapy can kill the tumor cells that were disseminated during the operation and the tumor cells remaining in the trauma surface, and the immediate postoperative perfusion reduces the patient’s 5-year recurrence rate by 35%. Early instillation of bladder cancer is a kind of adjuvant treatment method, which is commonly used in the clinic for patients who have undergone transurethral bladder tumor electrodessication surgery. Although the lesion has been removed from the patient’s body through surgery, but in order to prevent postoperative recurrence, those who meet the requirements are often recommended to undergo instillation chemotherapy. Early perfusion is 4 to 8 weeks after surgery, once a week, followed by maintenance perfusion, once a month, for 6 to 12 months. Perfusion chemotherapy is not suitable for all patients. Before starting the treatment, the doctor needs to carefully evaluate the patient’s condition and physical status, and if there is any discomfort during the perfusion process, the patient should consult the doctor in a timely manner.